Interferon beta-1b

Also Known As: Interferon beta-1b, Betaseron, Extavia, Ziferon

Interferon beta-1b (tradenames Betaferon, Betaseron (North America), Extavia and ZIFERON) is a drug in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. It is administered by sub-cutaneous injection and has been shown to slow the advance of the affliction as well as reduce the frequency of attacks.

It is believed that interferon-beta based drugs achieve their beneficial effect on MS progress via their anti-inflammatory properties. Studies have also determined that interferon-beta improves the integrity of the blood-brain barrier (BBB)—which generally breaks down in MS patients, allowing increasing amounts of undesirable substances to reach the brain. This strengthening of the BBB may be a contributing factor to interferon-beta's beneficial effects. These studies were carried out in vitro, so it does not necessarily mean it works the same in people.

Patients taking Interferon beta-1b may develop neutralizing antibodies to the medication.Reference link

Betaferon/Betaseron is marketed today by Bayer HealthCare. The originator was Schering AG (Berlex in North America), now part of Bayer HealthCare. Novartis has also introduced Extavia, a new brand of interferon beta-1b, in 2009.

Print this Page

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

Effectiveness:
  • 0 = No improvement or Worse
  • 1 = Slight improvement
  • 2 = Moderate Improvement
  • 3 = Significant Improvement
  • 4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Embed

Complete a survey on Interferon beta-1b to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.